Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $6,192,099.39 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 470,167 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the transaction, the chief executive officer directly owned 2,301,113 shares in the company, valued at $30,305,658.21. The trade was a 16.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Adaptive Biotechnologies Trading Up 5.8%

Adaptive Biotechnologies stock opened at $13.17 on Monday. The firm has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 1 year low of $6.68 and a 1 year high of $20.76. The business has a 50-day moving average of $16.55 and a 200-day moving average of $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the company posted ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. Research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter worth $30,000. EverSource Wealth Advisors LLC increased its holdings in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at about $51,000. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. BTIG Research raised their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. increased their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.